Page 118 - MemoriaEHD-Eng

RESEARCH GROUPS

ñá

é
PROGRAMME:
á
G1088
Gastrointestinal é
Inflammation and Motility

Group Members
Lead Researcher
íé
Pérez Gisbert, Javier
STAFF MEMBERS
Duran Vegue, Almudena

Marin Gomez, Alicia C.
Contact:
McNicholl, Adrian Gerald

Fundación para la Investigación Biomédica. Muoz Linares, Pablo
del Hospital Universitario La Princesa.
ASSOCIATED MEMBERS
Phone: (+34) 91 309 39 11 · E.mail: [email protected]
Website: www.eiilaprincesa.org Abad Santos, Francisco
Chaparro Snchez, Mara
http://www.madrid.org/hospitaldelaprincesa/digestivo
Gamallo Amat, Carlos
Gonzlez Guijarro, Luis
Main lines of research
Mat Jimnez, Jos

Parra Cid, Trinidad Focuses on the understanding and management of Helicobacter pylori infection and
Santander Vaquero, Cecilio Inflammatory Bowel Disease (IBD). Clinical and epidemiological projects are perfor-

Torrado, Santiago
med coordinating networks of gastroenterologists from over 30 Spanish hospitals.
Traslational research lines:

• Gastric H. pylori induced proliferation/apoptosis

Effect of infection status, bacterial strain, patients’ genotype and the type and

severity of gastric lesions; Comparison pre and post eradication; Genetic and epi-
demiological factors in the progression of pre-cancerous lesions

• Angiogenesis and lymphangiogenesis in IBD

Ulcerative colitis vs. Crohn’s disease; Correlation with clinical and disease course
variables; Effect of the therapy (immune suppressors and biologic treatments)

• Immunity in IBD

Vaccination optimization in IBD patients; Immunological alterations after Hepatitis
B virus (HBV) vaccination; Predictive variables to HBV vaccination response; Me-

chanisms of production of antibodies against anti-TNF treatments, and their rela-
tion with treatment response

• New diagnostic methods
13
20
Serologic diagnosis of Duodenal Ulcer; Diagnosis of H. pylori infection with novel T
monoclonal fecal kits; Clinical utility of biological markers like fecal calprotectin R
PO
and lactoferrin as well as azathioprine metabolites; Genetic/Pharmacogenetics and E
individualized medicine in IBD; Improved diagnosis of concomitant diseases in IBD
L R
A
• New therapies
NU
N
Routine-data-based studies on the efficacy and safety of novel and traditional A
/
treatments on H. pylori eradication; New antibiotic combinations and formulations HD
(hydrogels) for H. pylori treatment; New antibiotic indications for H. pylori; Pho- E
todynamic therapy applied to the inactivation of H. pylori; Identification of new ER
IB
therapeutic targets in IBD
C

118